Expanded Access Program for Dolutegravir

ViiV Healthcare recently announced that the dolutegravir Expanded Access Program (EAP) is now open and accepting participants in the U.S. and Canada.

Dolutegravir (DTG) is an integrase inhibitor under development as a treatment for HIV-1 infection. Phase 2b data presented at the recent CROI meeting in Seattle showed that dolutegravir administered once daily with two NRTIs was associated with good treatment responses at all doses. Those who were on the 50 mg dolutegravir dose and had a viral load of less than 50 copies (undetectable) at 96 weeks (88%) compared favorably with those on Sustiva (72%).

The EAP has been designed to provide access to Shionogi-ViiV Healthcare’s dolutegravir in an open-label protocol program to adults living with HIV who have documented Isentress (raltegravir) or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for therapy.

For Europe and the International region, it's expected that the EAP will start to open in March/April 2012 as local regulatory and ethics approvals are obtained. For more information, please visit: http://www.dolutegravir-eap.com.

The Friends of AIDS Foundation is dedicated to enhancing the quality of life for HIV positive individuals and empowering people to make healthy choices to prevent the spread of the HIV virus. To learn more about The Friends of AIDS Foundation, please visit: http://www.friendsofaids.org.

TOGETHER WE REMAIN STRONG!